Jason Butler
Stock Analyst at JMP Securities
(4.43)
# 303
Out of 4,941 analysts
139
Total ratings
47.95%
Success rate
21.55%
Average return
Main Sectors:
Stocks Rated by Jason Butler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABVX ABIVAX Société Anonyme | Maintains: Market Outperform | $33 → $95 | $69.00 | +37.68% | 4 | Jul 23, 2025 | |
| RAPP Rapport Therapeutics | Reiterates: Market Outperform | $28 | $14.28 | +96.08% | 2 | Jul 8, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Market Outperform | $37 | $24.84 | +48.98% | 14 | Jun 26, 2025 | |
| GHRS GH Research | Reiterates: Market Outperform | $39 | $11.80 | +230.51% | 5 | Jun 24, 2025 | |
| PGEN Precigen | Reiterates: Market Outperform | $6 | $1.74 | +244.83% | 11 | Jun 12, 2025 | |
| PRTA Prothena Corporation | Maintains: Market Outperform | $78 → $29 | $7.67 | +278.10% | 10 | May 27, 2025 | |
| TTD The Trade Desk | Maintains: Market Outperform | $115 → $100 | $53.18 | +88.06% | 1 | May 9, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Market Outperform | $42 → $38 | $16.89 | +125.05% | 8 | May 7, 2025 | |
| CYTK Cytokinetics | Reiterates: Market Outperform | $78 | $33.23 | +134.73% | 16 | Apr 10, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Market Outperform | $17 → $18 | $11.70 | +53.85% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $4 | $1.85 | +116.80% | 7 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $696 → $701 | $638.90 | +9.72% | 8 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $29 → $33 | $10.48 | +215.04% | 1 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $8 → $9 | $5.94 | +51.52% | 8 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $72 → $73 | $62.89 | +16.08% | 13 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $9 | $3.86 | +133.16% | 7 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.38 | - | 7 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $10.07 | +88.68% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $22 | $0.84 | +2,530.63% | 1 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.76 | - | 1 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $42,000 | $7.04 | +596,109.81% | 1 | Dec 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $111 → $116 | $6.49 | +1,687.37% | 4 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $9 | $3.35 | +168.66% | 1 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.56 | - | 1 | Dec 2, 2020 |
ABIVAX Société Anonyme
Jul 23, 2025
Maintains: Market Outperform
Price Target: $33 → $95
Current: $69.00
Upside: +37.68%
Rapport Therapeutics
Jul 8, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $14.28
Upside: +96.08%
ACADIA Pharmaceuticals
Jun 26, 2025
Reiterates: Market Outperform
Price Target: $37
Current: $24.84
Upside: +48.98%
GH Research
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $39
Current: $11.80
Upside: +230.51%
Precigen
Jun 12, 2025
Reiterates: Market Outperform
Price Target: $6
Current: $1.74
Upside: +244.83%
Prothena Corporation
May 27, 2025
Maintains: Market Outperform
Price Target: $78 → $29
Current: $7.67
Upside: +278.10%
The Trade Desk
May 9, 2025
Maintains: Market Outperform
Price Target: $115 → $100
Current: $53.18
Upside: +88.06%
Viridian Therapeutics
May 7, 2025
Maintains: Market Outperform
Price Target: $42 → $38
Current: $16.89
Upside: +125.05%
Cytokinetics
Apr 10, 2025
Reiterates: Market Outperform
Price Target: $78
Current: $33.23
Upside: +134.73%
Zevra Therapeutics
Mar 12, 2025
Maintains: Market Outperform
Price Target: $17 → $18
Current: $11.70
Upside: +53.85%
Mar 5, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $1.85
Upside: +116.80%
Feb 28, 2025
Maintains: Outperform
Price Target: $696 → $701
Current: $638.90
Upside: +9.72%
Feb 21, 2025
Maintains: Market Outperform
Price Target: $29 → $33
Current: $10.48
Upside: +215.04%
Feb 13, 2025
Maintains: Market Outperform
Price Target: $8 → $9
Current: $5.94
Upside: +51.52%
Nov 1, 2024
Maintains: Market Outperform
Price Target: $72 → $73
Current: $62.89
Upside: +16.08%
Oct 8, 2024
Reiterates: Market Outperform
Price Target: $9
Current: $3.86
Upside: +133.16%
Sep 4, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $0.38
Upside: -
Apr 9, 2024
Reiterates: Market Outperform
Price Target: $19
Current: $10.07
Upside: +88.68%
Sep 28, 2023
Initiates: Market Outperform
Price Target: $22
Current: $0.84
Upside: +2,530.63%
Oct 17, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.76
Upside: -
Dec 15, 2021
Initiates: Market Outperform
Price Target: $42,000
Current: $7.04
Upside: +596,109.81%
Nov 23, 2021
Maintains: Market Outperform
Price Target: $111 → $116
Current: $6.49
Upside: +1,687.37%
Nov 8, 2021
Maintains: Market Outperform
Price Target: $7 → $9
Current: $3.35
Upside: +168.66%
Dec 2, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $0.56
Upside: -